Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 11/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182827 | 0.92 | MAPT (0.46) | KDM4EGAAMAPTMAPK1PDE4A | |
| SCHEMBL127280 | 0.90 | ALDH1A1 (0.39) | KDM4EGAAMAPTMAPK1TSHR | |
| SCHEMBL314353 | 0.85 | KDM4E (0.37) | KDM4EGAAMAPTPDE4APDE4B | |
| SCHEMBL316261 | 0.83 | CYP1A2 (0.41) | KDM4EMAPTMAPK1PDE4APDE4B | |
| SCHEMBL8674 | 0.83 | CA2 (0.46) | KDM4EMAPTMAPK1PDE4APDE4B | |
| SCHEMBL2459479 | 0.82 | L3MBTL1 (0.42) | KDM4EGAAMAPTTP53ALDH1A1 | |
| SCHEMBL27879858 | 0.82 | CA2 (0.37) | MAPK1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL182703 | 0.81 | L3MBTL1 (0.38) | MAPTMAPK1CA12CA1CA2 | |
| SCHEMBL6200525 | 0.81 | L3MBTL1 (0.41) | KDM4EGAAMAPTTP53ALDH1A1 | |
| SCHEMBL27494520 | 0.81 | CA2 (0.43) | KDM4EMAPTMAPK1PDE4ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114213353-A | Aryl-oxazole-oxazoline compound and preparation method and application thereof | 贵州大学 | 2022-03-22 | — | — | CN | claimed |
| CN-106995401-A | A kind of method for preparing high-optical-purity Apremilast | 浙江京新药业股份有限公司 | 2017-08-01 | — | — | CN | claimed |
| EP-3123864-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2017-02-01 | — | — | EP | claimed |
| CN-104744476-A | IMIDAZOPYRAZINE Syk INHIBITORS | GILEAD CONNECTICUT INC | 2015-07-01 | — | — | CN | claimed |
| US-20130267496-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-10-10 | — | — | US | claimed |
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-12 | — | — | US | claimed |
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| EP-2373169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | claimed |
| WO-2010068257-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| WO-1999064420-A1 | β-CARBOLINE COMPOUNDS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S (FR) | 1999-12-16 | — | — | WO | claimed |
| EP-0942902-A2 | NOVEL IMMUNOTHERAPEUTIC IMIDES/AMIDES | CELGENE CORPORATION (US) | 1999-09-22 | — | — | EP | claimed |
| US-5877200-A | Cyclic amides | CELGENE CORPORATION (US) | 1999-03-02 | — | — | US | claimed |
| WO-1998024763-A2 | IMMUNOTHERAPEUTIC IMIDES/AMIDES AS PDE IV AND TNF INHIBITORS | CELGENE CORPORATION (US) | 1998-06-11 | — | — | WO | claimed |
| US-5703098-A | INHIBITORS OF CYTOKINES INCLUDING TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-30 | — | — | US | claimed |
| US-5605914-A | INHIBITORS OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-02-25 | — | — | US | claimed |
| EP-0219756-B1 | Acrylic amides | SHELL INT RESEARCH (NL) | 1994-01-05 | — | — | EP | claimed |
| US-5231105-A | Ethylamine derivatives and antihypertensives containing the same | AJINOMOTO CO., INC. (JP) | 1993-07-27 | — | — | US | claimed |
| US-4910200-A | Agricultural fungicide | CELAMERCK GMBH & CO. KG (DE) | 1990-03-20 | — | — | US | claimed |
| EP-0219756-A1 | Acrylic amides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-04-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | KDM4E 1611/4885GAA 545/4885MAPT 3775/4885 |
| US-20130267496-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | KDM4E 1611/4885GAA 545/4885MAPT 3775/4885 |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | KDM4E 1611/4885GAA 545/4885MAPT 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.